TREANDA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Treanda, and when can generic versions of Treanda launch?

Treanda is a drug marketed by Cephalon and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-six patent family members in twenty-one countries.

The generic ingredient in TREANDA is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Treanda

A generic version of TREANDA was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7^th, 2022.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TREANDA?
What are the global sales for TREANDA?
What is Average Wholesale Price for TREANDA?

Summary for TREANDA

International Patents:	66
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	130
Clinical Trials:	107
Patent Applications:	2,130
Drug Prices:	Drug price information for TREANDA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TREANDA
What excipients (inactive ingredients) are in TREANDA?	TREANDA excipients list
DailyMed Link:	TREANDA at DailyMed

Drug patent expirations by year for TREANDA

Recent Clinical Trials for TREANDA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	Phase 3
Vaishalee Kenkre	Phase 1/Phase 2
University of Wisconsin, Madison	Phase 1/Phase 2

See all TREANDA clinical trials

Pharmacology for TREANDA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Paragraph IV (Patent) Challenges for TREANDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TREANDA	Injection	bendamustine hydrochloride	90 mg/mL, 0.5 mL and 2 mL in single- dose vials	022249	1	2014-06-19
TREANDA	Injection	bendamustine hydrochloride	25 mg/vial and 100 mg/vial	022249	10	2013-06-04

US Patents and Regulatory Information for TREANDA

TREANDA is protected by two US patents.

Patents protecting TREANDA

Bendamustine pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Solid forms of bendamustine hydrochloride
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;IV (INFUSION)	022249-002	May 1, 2009	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Cephalon	TREANDA	bendamustine hydrochloride	SOLUTION;IV (INFUSION)	022249-003	Sep 13, 2013		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;IV (INFUSION)	022249-002	May 1, 2009	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;IV (INFUSION)	022249-002	May 1, 2009	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;IV (INFUSION)	022249-001	Mar 20, 2008	AP	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for TREANDA

When does loss-of-exclusivity occur for TREANDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 09296734
Patent: Liquid formulations of bendamustine
Estimated Expiration: ⤷ Sign Up

Patent: 15207940
Patent: Liquid Formulations of Bendamustine
Estimated Expiration: ⤷ Sign Up

Patent: 16203246
Patent: Liquid formulations of bendamustine
Estimated Expiration: ⤷ Sign Up

Patent: 16247123
Patent: Liquid formulations of bendamustine
Estimated Expiration: ⤷ Sign Up

Patent: 18202107
Patent: Liquid formulations of bendamustine
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 35899
Patent: FORMULATIONS LIQUIDES DE BENDAMUSTINE (LIQUID FORMULATIONS OF BENDAMUSTINE)
Estimated Expiration: ⤷ Sign Up

China

Patent: 2164579
Patent: Liquid formulations of bendamustine
Estimated Expiration: ⤷ Sign Up

Patent: 4224703
Patent: Liquid Formulations Of Bendamustine
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 26306
Patent: FORMULATIONS LIQUIDES DE BENDAMUSTINE (LIQUID FORMULATIONS OF BENDAMUSTINE)
Estimated Expiration: ⤷ Sign Up

Patent: 89029
Patent: Formulations liquides de bendamustine (Liquid formulations of bendamustine)
Estimated Expiration: ⤷ Sign Up

Hong Kong

Patent: 11462
Patent: 苯達莫司汀的液體製劑 (LIQUID FORMULATIONS OF BENDAMUSTINE)
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 70335
Estimated Expiration: ⤷ Sign Up

Patent: 12503666
Estimated Expiration: ⤷ Sign Up

Mexico

Patent: 11002936
Patent: FORMULACIONES LIQUIDAS DE BENDAMUSTINA. (LIQUID FORMULATIONS OF BENDAMUSTINE.)
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TREANDA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
China	104224703	Liquid Formulations Of Bendamustine	⤷ Sign Up
Australia	2016247123	Liquid formulations of bendamustine	⤷ Sign Up
Hong Kong	1116073	BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS FOR LYOPHILISATION	⤷ Sign Up
Japan	2013056902	BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS	⤷ Sign Up
Taiwan	I472515		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration